Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780962 · ClinicalTrials.gov registry record · Phase 2
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
A Phase 2 study of Radiocontrast Nephropathy, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 399
- Enrollment target
- 1
- Study location
NCT00780962 is a Phase 2 study of Radiocontrast Nephropathy that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 399 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00780962, a Phase 2 study of Radiocontrast Nephropathy, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 399 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple agents have been studied to prevent radiocontrast nephropathy. One of these agents is N-Acetylcysteine. Previous trials to assess N-Acetylcysteine's efficacy in the prevention of contrast nephropathy have been promising. However, previous studies have limited applicability to the Emergency Department (ED) patient population for two reasons: * 1\) Many of the pretreatment strategies employed in these studies take several hours or even days to perform, which is not feasible in acutely ill ED patients. * 2\) Most of these studies were conducted in patients undergoing cardiac catheterization. This may be a very different population than patients in the ED undergoing abdominal or chest computed tomography. The investigators wish to study the efficacy of N-acetylcysteine as an agent to prevent radiocontrast nephropathy in ED patients undergoing computerized tomography. The investigators propose a randomized, double-blind, controlled trial comparing saline hydration plus N-acetylcysteine versus saline hydration alone. The hypothesis of this study is that N-acetylcysteine with normal saline will be more effective than saline alone in the prevention of radiocontrast nephropathy.
Conditions Studied
Interventions
- DRUG N-Acetylcysteine (NAC)
- DRUG 0.9% Sodium-chloride
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2007-10-16 |
| Est. Completion | 2010-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780962
The ClinicalTrials.gov registry entry for NCT00780962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 399 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radiocontrast Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which N-Acetylcysteine (NAC) is the first listed.
NCT00780962 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00780962 about?
NCT00780962 is a clinical study titled "N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients". Multiple agents have been studied to prevent radiocontrast nephropathy. One of these agents is N-Acetylcysteine. Previous trials to assess N-Acetylcysteine's efficacy in the prevention of contrast nephropathy have been promising. However, previous studies have limited applicability to the Emergency ...
What is the current status of trial NCT00780962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 399 participants. The study started on 2007-10-16. Estimated completion is 2010-08-09.
What conditions does trial NCT00780962 study?
This clinical trial studies the following conditions: Radiocontrast Nephropathy.
What interventions are being tested in trial NCT00780962?
The interventions under investigation include: N-Acetylcysteine (NAC) (DRUG), 0.9% Sodium-chloride (DRUG).
Who is sponsoring clinical trial NCT00780962?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00780962 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.